Market Newsdesk

GUELPH, ON, Nov. 23, 2020 /PRNewswire/ — Canadian Solar Inc. (the “Company”, or “Canadian Solar”) (NASDAQ: CSIQ), one of the world’s largest solar power companies, announced that it recently signed a power purchase agreement (“PPA”) with BTG Pactual (“BTG”, B3: BPAC11) and that it was awarded with two projects in a private auction by Furnas Centrais Elétricas (“Furnas”) for a total of 862 MWp in solar power projects in Brazil.

For the 12-year PPA with BTG, Canadian Solar will supply solar energy from a 170 MWp cluster of projects located in the State of Minas Gerais. The projects will start construction in 2021 and are expected to achieve commercial operation by the end of 2022. BTG is one of the main investment banks in Latin America and runs one of the largest energy trading businesses in Brazil.

Furnas will purchase solar energy from two Canadian Solar projects through a 15-year PPA. Canadian Solar will develop and build both Furnas projects totalling 692 MWp. One of them, will be located in the State of Ceará and will have a capacity of 260 MWp. The second project is located in the State of Piuaí and will have a capacity of 432 MWp. Both projects will start construction in 2022 and are expected to reach commercial operation by the end of 2023.

Furnas is a majority-controlled subsidiary of Centrais Elétricas Brasileiras S.A. – Eletrobras (“Eletrobras”, NYSE: EBR). Furnas’ business is mainly in energy generation, transmission and sales. It operates in 16 Brazilian states and is the owner of 21 hydro plants, 2 thermal plants, 1 wind farm and 30,000 kilometers of transmission lines. 

Dr. Shawn Qu

, Chairman and CEO of Canadian Solar, commented, “We are pleased to partner with BTG and Furnas to deliver clean solar energy to Brazilian consumers. I am also proud of our team’s great work in expanding our leadership position in the solar project development market in Brazil. After the 274 MWp in corporate PPAs that we signed earlier in June, the volume of projects secured in this PPA and auction is the largest in Canadian Solar’s history, and it increases our backlog of solar projects in Brazil with PPAs (or equivalent) to almost 2.2 GWp.”

“We are also making good progress on our project monetization strategy in Brazil, where we are in the process of forming a Brazilian Participation Fund for Infrastructure projects, or FIP-IE, which is on track to launch in 2021. This will help accelerate our growth in the Brazilian market as we optimize our capital allocation. More updates to come.”

All projects will use Canadian Solar’s latest, high power series 7 bifacial modules of up to 665 Wp.

About Canadian Solar Inc.

Canadian Solar was founded in 2001 in Canada and is one of the world’s largest solar power companies. It is a leading manufacturer of solar photovoltaic modules and provider of solar energy solutions and has a geographically diversified pipeline of utility-scale solar power projects in various stages of development. Over the past 19 years, Canadian Solar has successfully delivered over 49 GW of premium-quality, solar photovoltaic modules to customers in over 150 countries. Canadian Solar is one of the most bankable companies in the solar industry, having been publicly listed on NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

Safe Harbor/Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially. These statements are made under the “Safe Harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as “believes,” “expects,” “anticipates,” “intends,” “estimates,” the negative of these terms, or other comparable terminology. Factors that could cause actual results to differ include general business and economic conditions and the state of the solar industry; governmental support for the deployment of solar power; future available supplies of high-purity silicon; demand for end-use products by consumers and inventory levels of such products in the supply chain; changes in demand from significant customers; changes in demand from major markets such as Japan, the U.S., India and China; changes in customer order patterns; changes in product mix; capacity utilization; level of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility-scale project approval process; delays in utility-scale project construction; delays in the completion of project sales; delays in the process of qualifying to list the MSS subsidiary in the PRC; continued success in technological innovations and delivery of products with the features customers demand; shortage in supply of materials or capacity requirements; availability of financing; exchange rate fluctuations; litigation and other risks as described in the Company’s SEC filings, including its annual report on Form 20-F filed on April 28, 2020. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and Canadian Solar undertakes no duty to update such information, except as required under applicable law.

View original content:http://www.prnewswire.com/news-releases/canadian-solar-signs-a-total-of-862-mwp-in-solar-ppa-with-btg-and-auction-with-furnas-in-brazil-301178821.html

SOURCE Canadian Solar Inc.

NEW YORK, Nov. 23, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab and the radioisotope iodine-131 used in the Company’s lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs. Actinium owns issued or pending patents within the United States and globally covering composition of matter, formulation, methods of use, and methods of administration with potential coverage for 19 years or longer. Importantly, Actinium owns an issued patent in the US covering composition of matter, for which the Company expects validity until 2037. In addition, the Company owns a second issued US patent that further covers composition of matter, methods of use, and methods of administration for Iomab-B. The company has also received a notice of allowance in Europe for this second patent and expects it to be in force until 2036.

Iomab-B is currently being investigated in the ongoing pivotal Phase 3 SIERRA trial, which is over 75% enrolled, for targeted conditioning prior to potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory Acute Myeloid Leukemia (“R/R AML”).  In addition, Actinium is utilizing apamistamab with lower doses of iodine-131, known as Iomab-ACT, for targeted conditioning prior to gene therapy and adoptive cell therapy (“ACT”), namely CAR-T, including in its recently announced collaboration with Memorial Sloan Kettering Cancer Center that is supported by NIH STTR Fast Track grant funding.

“The continued protection of our lead asset Iomab-B, our Iomab-ACT program and apamistamab by a strong patent position is an important component of our development efforts, particularly as we approach the conclusion of our pivotal Phase 3 SIERRA trial for BMT conditioning in R/R AML The growth of BMT, ACT and Gene Therapy has highlighted the importance of conditioning and the need to move beyond non-targeted chemotherapy to increase the number of patients that could benefit from these potentially curative therapies. CD45 is an ideal target for conditioning applications given its unique expression on blood cancer cells and blood forming stem and immune cells and with no expression outside the hematopoietic or blood system,” said Dr. Dale Ludwig, Actinium’s Chief Scientific Officer. “Apamistamab is well characterized and its use in conditioning is supported by extensive clinical data across multiple clinical trials and indications. Our robust data shows that apamistamab has a favorable biodistribution profile that, together with our ARC technology, has significant advantages over other approaches such antibody drug conjugates that require payload internalization, making them impractical for targeting CD45. Further, our ARC approach allows us to use varying intensities of targeted radiation to achieve our desired conditioning outcome. With these important patents in place, and continued expansion of our patent portfolio in the US, EU and other select countries, we look forward to continuing to build out our targeted conditioning strategic business unit.”

About Iomab-B

Iomab-B is Actinium’s lead product candidate that is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above.  Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Iomab-B targets cells that express CD45, a pan-leukocytic antigen widely expressed on white blood cells with the monoclonal antibody, apamistamab (formerly BC8), labeled with the radioisotope, iodine-131. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient’s cancer and marrow cells. In a Phase 1/2 clinical study in 68 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced enabled 100% of patients to proceed to transplant with all patients achieving transplant engraftment by day 28. Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it has been studied in almost 300 patients in a number of blood cancer indications, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s disease, Non-Hodgkin lymphomas and multiple myeloma. Actinium obtained the worldwide, exclusive rights to apamistamab (BC8) and Iomab-B from the Fred Hutchinson Cancer Research Center. Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the U.S. Food and Drug Administration and the European Medicines Agency.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:

Clayton Robertson

Actinium Pharmaceuticals, Inc.
[email protected]

Hans Vitzthum

LifeSci Advisors, LLC
[email protected] 
(617) 430-7578

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-highlights-foundational-patents-covering-the-composition-of-apamistamab-antibody-and-iomab-b-antibody-radiation-conjugate-for-targeted-conditioning-until-2037-and-recent-eu-patent-activity-301178595.html

SOURCE Actinium Pharmaceuticals, Inc.

TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2020 and provides a corporate update.

Significant events and achievements during the third quarter 2020 and subsequent period:

• Reported positive results from a pre-planned interim analysis of GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. The Data Monitoring Committee (DMC) found statistically significant evidence favoring treatment with motixafortide in the primary endpoint, and subsequently issued a recommendation to cease patient enrollment immediately. In accordance with the DMC’s recommendation, study enrollment was completed at 122 patients (instead of 177 as originally planned). SCM is the Company’s most efficient path to registration;
• Announced initiation of Phase 2 investigator-initiated study of motixafortide in combination with LIBTAYO^® and chemotherapy in first-line PDAC. The study is being run by Columbia University;
• Announced initiation of investigator-initiated Phase 1b study, led by Wolfson Medical Center in Holon, Israel, to evaluate motixafortide in patients hospitalized with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections;
• Renewed study enrollment in Part of Phase 1/2a trial for AGI-134, which had been temporarily suspended in the second quarter of 2020 due to clinical operating risks associated with the COVID-19 pandemic;
• Conducted interim analysis for Phase 2b BLAST study in consolidation AML; analysis did not demonstrate statistically significant effect in primary endpoint; DMC recommended not to continue the study.

“The past several months have been very exciting for BioLineRx, highlighted by the very positive result of the interim analysis of our Phase 3 GENESIS study in stem cell mobilization” stated Philip Serlin, Chief Executive Officer of BioLineRx. “A statistically significant benefit in the primary endpoint was observed by combining motixafortide with the standard of care, G-CSF, leading the DMC to recommend that we cease study enrollment at 122 patients, instead of the 177 originally planned. We look forward to publishing final results of the study in the first half of next year, as we continue to advance motixafortide toward registration.

“With regard to the Phase 2b BLAST study in consolidation AML, based on the results of the interim analysis, the DMC recommended not to continue the study. Although we are disappointed by this outcome, particularly following the positive results that we previously observed in our Phase 1/2a study of motixafortide with cytarabine in relapsed/refractory AML, we continue to believe in the relevance of CXCR4 as a viable target in other AML treatment lines, such as rr/AML and induction treatment. We will decide on next steps in AML once we’ve had a chance to review and analyze the unblinded data, including detailed biomarker and subpopulation data, from this study. I would also like to express our gratitude to the University of Halle, as study sponsor, and Dr. Carsten Müller-Tidow, as principal study investigator, as well as the other investigators and the patients who made this important trial possible.

“Finally, in the coming weeks, we plan to announce full results, including progression free survival (PFS) and overall survival (OS) data, on all study patients from the triple combination arm of our Phase 2a COMBAT/KEYNOTE-202 study in second-line PDAC. We previously shared preliminary positive overall response rate and disease control rate data, on approximately half of the patients enrolled in this study arm, at last year’s ESMO IO conference, and we remain optimistic that the combination of motixafortide and KEYTRUDA^®, together with chemotherapy, will prove beneficial to survival as well.

“The significant and growing body of data that we are compiling on motixafortide, including the strikingly positive results of the interim analysis in the GENESIS phase 3 study reported last month, reassure us about the unique characteristics of motixafortide as the best-in-class CXCR4 antagonist, and confirm our belief that this promising compound can potentially serve as the backbone of combination therapies to treat a broad range of solid tumor and hematological cancers,” Mr. Serlin concluded.

Upcoming Expected Milestones

• Overall final results, including PFS and OS data, from the COMBAT/KEYNOTE-202 Phase 2a triple combination study in second-line PDAC by the end of 2020;
• Final results from the Phase 3 GENESIS trial in SCM in the first half of 2021;
• Preliminary results of the Phase 1b study in ARDS in the first half of 2021;
• Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of 2021;
• Data from the Columbia University-initiated study of motixafortide in combination with LIBTAYO^® and chemotherapy in first-line PDAC in mid-2022;

Financial Results for the Quarter Ended September 30, 2020

Research and development expenses for the three months ended September 30, 2020 were $3.5 million, a decrease of $2.1 million compared to $5.6 million for the comparable period in 2019. The decrease resulted primarily from termination of the BATTLE clinical study for motixafortide in 2019 and from lower expenses associated with the AGI-134 study, as well as a decrease in payroll and related expenses due to a Company-wide salary reduction related to the COVID-19 pandemic carried out in the second and third quarters of 2020. Research and development expenses for the nine months ended September 30, 2020 were $13.5 million, a decrease of $1.7 million, compared to $15.2 million for the nine months ended September 30, 2019. The decrease resulted primarily from lower expenses associated with the motixafortide COMBAT clinical trialand the AGI-134 study, as well as a decrease in payroll and related expenses due to a Company-wide salary reduction related to the COVID-19 pandemic mentioned above.

Sales and marketing expenses for three months ended September 30, 2020 were $0.3 million, an increase of $0.1 million compared to $0.2 million for the comparable period in 2019. The increase resulted primarily from consultancy services and market research for motixafortide offset by a decrease in payroll and related expenses related to a reduction in headcount. Sales and marketing expenses for the nine months ended September 30, 2020 were $0.7 million, similar to the comparable period in 2019.

General and administrative expenses for the three months ended September 30, 2020 were $0.9, similar to the comparable period in 2019. General and administrative expenses for the nine months ended September 30, 2020 were $2.8 million, similar to the comparable period in 2019.

The Company’s operating loss for the three months ended September 30, 2020 amounted to $4.6 million, compared to an operating loss of $6.6 million for the comparable period in 2019.The Company’s operating loss for the nine months ended September 30, 2020 was $17.1 million, compared to $18.7 million for the comparable period in 2019.

Non-operating income (expenses) for the three- and nine-month periods ended September 30, 2020 and 2019 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses and issuance expenses of the Company’s ATM program.

Net financial expenses for the three months ended September 30, 2020 amounted to $0.3 million compared to net financial expenses of $0.4 million for the comparable period in 2019. Net financial expenses for both periods primarily relate to interest paid on loans, offset by investment income earned on bank deposits. Net financial expenses for the nine months ended September 30, 2020 amounted to $0.9 million, similar to the comparable period in 2019. Net financial expenses for both periods primarily relate to interest paid on loans, offset by investment income earned on bank deposits.

The Company’s net loss for the three months ended September 30, 2020 amounted to $4.6 million, compared with a net loss of $3.9 million for the comparable period in 2019. The Company’s net loss for the nine months ended September 30, 2020 amounted to $18.0 million, compared with a net loss of $15.6 million for the comparable period in 2019.

The Company held $20.8 million in cash, cash equivalents and short-term bank deposits as of September 30, 2020.

Net cash used in operating activities was $17.8 million for the nine months ended September 30, 2020, compared with net cash used in operating activities of $17.2 million for the nine months ended September 30, 2019. The $0.6 million increase in net cash used in operating activities during the nine-month period in 2020 was primarily the result of the decrease in accounts payable and accruals in the 2020 period.

Net cash provided by investing activities was $8.1 million for the nine months ended September 30, 2020, compared to net cash provided by investing activities of $2.1 million for the nine months ended September 30, 2019. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits.

Net cash provided by financing activities was $10.9 million for the nine months ended September 30, 2020, compared to net cash provided by financing activities of $16.6 million for the nine months ended September 30, 2019. The cash flows in 2020 primarily reflect the May and June financings and the net proceeds from the Company’s ATM program, offset by repayments of the loan from Kreos Capital. The cash flows in 2019 primarily reflect the underwritten public offering of our ADSs in February 2019, as well as net proceeds from the ATM facility.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, November 23, 2020 at 10:00 a.m. EST. To access the conference call, please dial +1-866-744-5399 from the US or +972-3-918-0664 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until November 25, 2020; please dial +1-877-456-0009 from the US or +972-3-925-5929 internationally.

(Tables follow)

About
BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company’s lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and for which positive data in respect of the study’s primary endpoint was recently announced from an interim analysis, resulting in early cessation of recruitment. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA^® and chemotherapy under a collaboration agreement with MSD.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx’s preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx’s therapeutic candidates; BioLineRx’s ability to establish and maintain corporate collaborations; BioLineRx’s ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx’s industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx’s business. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthy

LifeSci Advisors, LLC
+1-212-915-2564
[email protected]

 

     

 

 

 

BioLineRx Ltd.
CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY
(UNAUDITED)

 

 

 

 

 

View original content:http://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2020-financial-results-and-provides-corporate-update-301178794.html

SOURCE BioLineRx Ltd.

VICTORIA, BC, Nov. 23, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected more than ten, unique monoclonal antibodies for further preclinical development.

The Polytope™ antibodies can be combined to create up to twelve unique cocktail therapies containing mixtures of two, three or four antibodies, each of which has been shown to work synergistically to prevent viral entry into cells in vitro. The Company announced today that it has nominated the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing. The upcoming pre-clinical trial will examine the safety, tolerability and efficacy of the proposed therapeutic cocktail in the well-defined, SARS-CoV-2, Syrian hamster model.

“We are excited to reach this milestone in what has been a very comprehensive Covid-19 therapeutic study aimed at treating disease caused by all Coronavirus variants, not to be thwarted by the ongoing mutations of the rapidly circulating virus”, said ImmunoPrecise CEO, Dr. Jennifer Bath. “Our scientific team chose a path of rigorous investigation to arrive at a diverse set of functional and meaningful candidates to combine into what we believe will be an effective therapy against both current and future strains of SARS-CoV-2. We did not sacrifice quality and we believe our approach is the suitable and effectual path.”

Antibodies not only cure diseased individuals, they may provide immediate protection with a single injection to exposed individuals or asymptomatic carriers, something a vaccine cannot do, enabling containment of new outbreaks. ImmunoPrecise’s Polytope therapy was designed to provide additional potential benefits as a means of long-term weaponry, a cocktail therapy designed with the goal of protecting against disease that could potentially be caused by novel mutations of the virus not covered by current vaccines and therapies.

The Company believes their approach using a well-characterized, monoclonal antibody cocktail to treat Covid-19 patients has high potential for fighting not only the most prevalent strains of SARS-CoV-2, but also the many alternate forms circulating today, as well as potential new variants of the virus in the future.

IPA’s curated antibody mixtures or “cocktails” have been shown to bind to multiple regions of the spike protein of the virus, including novel variations of the virus, caused by mutations, that have been identified and published in literature. The Company’s antibodies provide a clear boost in neutralization potency beyond what can be achieved with individual monoclonal antibodies alone, suggesting a synergy that may allow for lower dosing. Furthermore, engaging multiple antibodies in the fight against the virus has the potential to stimulate different mechanisms from the immune response to help clear infection, thereby enhancing overall clearance of the virus and aiding in recovery.

“Antibody cocktails that achieve full neutralization are advantageous over monotherapies because a single antibody is vulnerable to being escaped by even one mutation in the virus, depending on where that mutation occurs”, states Dr. Yasmina Abdiche, CSO of ImmunoPrecise.  “In contrast, our cocktail engages multiple antibodies at once, broadening what we refer to as the “epitope footprint”, or the regions on the virus where the antibodies bind. This provides insurance that the mutating virus cannot evade the treatment, which is a continuous threat as pathogens evolve”, added Dr. Abdiche.

The Companies antibody cocktails were designed specifically with the intent to address the high mutation rates found in RNA viruses (such as SARS-CoV-2), which mutate up to a million times faster than human DNA—and which have the possibility of correlating with an increased ability to cause disease. These higher mutation rates increase the chance of introducing traits which are considered advantageous to the virus.

“In fact, as anticipated, there are hundreds of documented mutations in the binding domain of the virus’ spike protein, which also happens to be the region most companies are targeting. A few of these mutations are now emerging as significant”, stated Dr. Ilse Roodink, IPA’s Coronavirus global Program Lead. “This creates a ‘moving target situation’, underpinning the importance of deploying numerous antibodies to attack the virus in concert, and building insurance into our cocktail therapy that it will remain effective as the virus continues to evolve”.

Pre-clinical manufacturing of the fully human lead, 4-mAb candidates is underway, with the pre-clinical studies scheduled to launch in early January in the Netherlands. The Company is also producing pre-clinical batches of additional, validated candidates to provide a panel of alternate options to modify the coverage of therapeutic cocktails if ever needed, to continue to combat future and/or seasonal variants of the virus.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. For further information, visit www.immunoprecise.com or contact [email protected].

About IPA’s SARS Polytope™ Therapies
Monoclonal antibodies were derived from several animal species, including humans, llama, rabbits and transgenic OmniAb® (humanized) animals to access a broad epitope coverage. IPA exploits multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes. In a global effort involving its scientists in North America and Europe, IPA has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend”, “should” and similar expressions to identify forward-looking statements and include the Company’s beliefs with respect to the potential for its antibodies to be further developed or approved to treat COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the previous quarter ended July 31st, 2020 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

View original content to download multimedia:http://www.prnewswire.com/news-releases/ipa-selects-polytope-formulations-for-pre-clinical-studies-301178805.html

SOURCE ImmunoPrecise Antibodies Ltd.

Else’s single and 4-Pack offerings reach #1 and #2 respectively on Amazon’s best-selling new release list

VANCOUVER, BC, Nov. 23, 2020 /PRNewswire/ – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YF) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company, is pleased to announce that its Plant-Based Complete Nutrition for Toddlers was ranked the number one (top) selling product on Amazon’s Hot New Releases in the Baby and Toddler Formula Category. As of November 17^th, the product’s single and 4-pack varieties took the first and second spots on the list respectively.   

“We are overwhelmed with excitement by the demand we are seeing for our Toddler Nutrition on the Amazon platform,” said Mrs. Hamutal Yitzhak, CEO and Co-Founder of Else. “The strong uptake confirms that U.S. parents are looking for novel healthy nutrition alternatives for their children.”. This response echoes the consumer feedback we have been receiving via our online store and brick and mortar retail channels,” she added.

Else Nutrition announced earlier this week that is has commenced shipment of its product with KeHE Distributors. Just in time for the holiday season, Else’s Plant-Based Complete Nutrition for Toddlers will be on the shelves of numerous U.S. retail stores, including a soon-to-be announced, national grocery chain.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/else-nutrition-is-1-on-amazons-best-selling-hot-new-releases-in-baby–toddler-formula-category-301178800.html

SOURCE Else Nutrition Holdings Inc.

BENTONVILLE, Ark., Nov. 23, 2020 /PRNewswire/ — Glucose Health, Inc. (OTC: GLUC) is pleased to provide three important corporate updates:

1)  Last week, GLUCODOWN® Diabetic Friendly “Enhanced Water” Drink Mixes successfully completed their final step of a year-long development process – a production trial. The objective of the production trial was to confirm and refine as necessary, production methods and parameters to ensure that new GLUCODOWN® Drink Mixes achieve the same category leading standard of quality as GLUCODOWN® Tea Mixes – themselves, the most nutritious, efficacious and at the same time, delicious, diabetic friendly functional beverages in America.

All ingredients comprising GLUCODOWN® Drink Mixes were staged and processed utilizing personnel and pilot scale equipment located at the Company’s manufacturing partner facility in Fairbault, Minnesota.  The Company is pleased to advise that GLUCODOWN® Diabetic Friendly “Enhanced Water” Drink Mixes are ready for market introduction and a first commercial production run is set for January 2021. A total of seven GLUCODOWN® Drink Mix flavors have been developed. The first four flavors to be produced are: GLUCODOWN® Diabetic Friendly Watermelon, Cherry, Peach-Mango and Strawberry-Banana.

2)  An all-new GLUCODOWN® consumer information website has been unveiled (www.glucodown.com). The new website features both GLUCODOWN® Diabetic Friendly Tea Mixes and Drink Mixes plus future products such as GLUCODOWN® Cappuccino and Horchata. The new website includes high-quality video of the Company’s TV commercials and an enhanced “HOW IT WORKS” section detailing ingredients in the GLUCODOWN® formula. 

3)  YTD GROSS PROFIT MARGIN DOUBLES:  On April 22, 2020, the Company stated its four strategic goals for fiscal 2020. Strategic Goal number four was:

“Increase Profit Margins. The company expects to increase profit margins through improved production methods and cost-control and selected retailer product price increases.”

For the nine-months of fiscal 2020 ended September 30, 2020, gross profit margin was 46% compared to 22% for the same nine-month period in 2019. Demonstrating the pricing power of GLUCODOWN® – prices at Amazon were increased from $12.99 to $13.49 in the first quarter of 2020. Following the price increases, Amazon sales increased by triple-digit multiples. Additionally, in the third quarter, the Company reviewed its accounting policies and adopted industry standard accounting procedures with respect to Amazon’s consumer fulfillment, which further increased gross profit margin. 

With its introduction in 2018, GLUCODOWN® defined an entirely new and distinct category of functional beverage – diabetic friendly iced tea. Now, the GLUCODOWN® brand has achieved another beverage industry first – diabetic friendly “enhanced water” drink mixes. The “enhanced water” beverage category is calculated by Fortune Business Insights to grow to $18 billion in annual revenues by 2025.³ 

In summation, by specializing in producing delicious functional beverages nutritionally appropriate¹ for the nation’s 100+ million pre and Type-2 diabetics, GLUCODOWN® is uniquely and strongly positioned among all up & coming beverage companies in America.  

About Glucose Health, Inc. (OTC: GLUC)

Manufactured by Glucose Health, Inc., GLUCODOWN® functional beverages are formulated for the diabetic/adult nutrition retail category. More than 100 million Americans are estimated to be diabetic or pre-diabetic, by the Centers for Disease Control and Prevention.² GLUCODOWN® provides these consumers, and increasingly many other health-conscious consumers such as followers of a KETO diet, with a nutritious, efficacious and delicious beverage option. Glucose Health, Inc. is a publicly traded company with the ticker symbol OTC: GLUC.

For more GLUC news visit
www.glucosehealthinc.com

¹ For citations visit www.glucodown.com/clinical-data 

²
National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services.

³ https://www.globenewswire.com/news-release/2020/05/14/2033658/0/en/Functional-Water-Market-Size-to-Worth-USD-18-24-Billion-by-2025-Advancements-in-Packaging-Technology-to-Augment-Growth-Says-Fortune-Business-Insights.html

Contact:

Murray Fleming

Glucose Health, Inc.
[email protected]
(479) 802-3827

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/glucodown-enhanced-water-drink-mixes-successfully-complete-production-trial-new-glucodown-website-unveiled-ytd-gross-profit-margin-doubles-301178622.html

SOURCE Glucose Health, Inc.

CHICAGO, Nov. 23, 2020 /PRNewswire/ — United announced today it is expanding its customer COVID-19 testing efforts to include flights out of Houston to select destinations in Latin America and the Caribbean. Starting for flights departing on December 7, customers originating from George Bush Intercontinental Airport (IAH) will have the option to take a self-collected, mail-in test that meets local entry requirements for the following destinations, allowing them to reunite with family or start their vacation immediately:

“Widespread testing is key to unlocking international borders and safely reopening global travel. This is particularly important for our customers in Houston, who rely on United to keep them connected with their family and friends in Latin America and the Caribbean,” said Toby Enqvist, chief customer officer for United. “We’ll continue to lead the way on testing – United was the first to announce a customer COVID-19 testing program and the first to offer free tests on flights across the Atlantic – and we’ll look at new, innovative ways to make the travel experience even safer.”

The self-collected, mail-in COVID-19 test is $119. The test will be administered by Advanced Diagnostic Laboratory (ADL) and processed at their COVID-19 testing laboratory in San Antonio, Texas. United will reach out to customers 14 days ahead of their flights to provide instructions on ordering a test and the testing process. United encourages customers to research the local requirements for further questions specific to their destination. Customers are advised to take the tests 72 hours before departure and should expect to receive results via email within 24-48 hours of mailing in their test.

“As the energy capital of the world and most diverse city in the United States, Houston plays an influential role in linking global economies,” said Sylvester Turner, City of Houston mayor. “As we fight against a second wave of the coronavirus, the private and public sectors, with guidance from public health experts, must work collaboratively and judiciously to reopen the global economy. Although a vaccine would be the ultimate solution, United’s expansion of its customer testing program is a step in the right direction. I commend United for their leadership and forward-thinking.”

ADL’s self-collection kit includes a plastic tube, a nasal swab and instructions on how to properly collect a specimen. ADL’s telehealth system will be available to support customers traveling to countries that require a health care professional to supervise the COVID-19 test. United has worked closely with officials in each country to ensure that any customer – both visitors and nationals returning home – who tests negative will be able to enter the country.

“Accurate and reliable testing is not only critical to reducing the spread of COVID-19, but essential in helping get this virus under control,” said Stan Crawford, chief operations officer for ADL. “We are invested in United’s commitment to ensuring customers not only meet their destination’s entry requirements but that, when they do travel, they do so in a way that is safer.”

Click here for b-roll and visual assets of ADL’s self-collection kit and testing 

In addition to adding another key element to its layered approach to safety, United has also seen a positive impact on travel demand and significant increases in customer load factors and revenue when testing options are available. For example, after United announced its COVID-19 test for customers traveling from San Francisco to Hawaii and allowing them to avoid a 14-day quarantine, the airline saw a nearly 95% increase in passengers compared to the prior two-week period. Last week, United launched the world’s first free transatlantic COVID-19 testing pilot between Newark Liberty International Airport and London Heathrow Airport. Through this pilot program, all crew members and customers over the age of two on select flights will be required to take a rapid COVID-19 test and provide a negative result in order to take the flight, ensuring that everyone on board over the age of two has tested negative before departure.

A safer travel experience: United CleanPlus
^SM

Since the start of the pandemic, United has been a leader in enacting new policies and innovations designed to keep employees and passengers safer when traveling. It was the first U.S. airline to mandate masks for flight attendants, quickly following with all customers and employees. United was also among the first U.S. carriers to announce it wouldn’t permit customers who refused to comply with the airline’s mandatory mask policy to fly with them while the face mask policy is in place. United was also the first U.S. airline to roll out touchless check-in for customers with bags, and the first to require passengers take an online health assessment before traveling. United is applying Zoono Microbe Shield, an EPA-registered antimicrobial coating that forms a long-lasting bond with surfaces and inhibits the growth of microbes, to its entire mainline and express fleet before the end of the year. 

The latest research, including a recent study conducted by the U.S. Department of Defense, shows COVID-19 exposure risk on board United aircraft is almost zero due to the airline’s advanced air filtration systems, mandated mask policy and diligent cleaning protocols.

For more details on all the ways United is helping keep customers safe during their journey, please visit united.com/cleanplus.

About United

United’s shared purpose is “Connecting People. Uniting the World.” For more information, visit united.com, follow @United on Twitter and Instagram or connect on Facebook. The common stock of United’s parent, United Airlines Holdings, Inc., is traded on the Nasdaq under the symbol “UAL”.

About Advanced Diagnostic Laboratory

Advanced Diagnostic Laboratory (ADL) is a leader in scientific testing standards for the COVID-19 virus, both in the U.S. and internationally. Located in San Antonio, Texas, ADL has over 80 years of combined experience in clinical diagnostic testing procedures and works globally with local communities to provide safe and healthy lifestyles. For more information, call ADL at 1.800.834.3522 or visit our website at ADLHealth.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/united-introduces-customer-covid-19-testing-from-houston-to-latin-american-and-caribbean-destinations-301178574.html

SOURCE United Airlines

DULUTH, Ga., Nov. 23, 2020 /PRNewswire/ — Asbury Automotive Group, Inc. (NYSE: ABG) (“Asbury” or the “Company”), one of the largest automotive retail and service companies in the U.S., announced today that it will unveil Clicklane— a communications technology ecosystem that allows for a true end-to-end online car-buying and selling experience. The Company previously scheduled the call for November 16^th, but chose to reschedule due to a trademark issue that resulted in changing the online platform name from Glovebox to Clicklane.

About Asbury Automotive Group, Inc.
Asbury Automotive Group, Inc. (“Asbury”), a Fortune 500 company headquartered in Duluth, GA, is one of the largest automotive retailers in the U.S.  Asbury currently operates 89 dealerships, consisting of 112 franchises, representing 31 domestic and foreign brands of vehicles.  Asbury also operates 25 collision repair centers.  Asbury offers customers an extensive range of automotive products and services, including new and used vehicle sales and related financing and insurance, vehicle maintenance and repair services, replacement parts and service contracts.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical fact, and may include statements relating to goals, plans, expectations, projections regarding the expected benefits of its end-to-end car-buying solution, management’s plans, projections and objectives for future operations, scale and performance, integration plans and expected synergies from acquisitions, our financial position, results of operations, market position, capital allocation strategy, business strategy and expectations of our management with respect to, among other things: changes in general economic and business conditions, including the impact of COVID-19 on the automotive industry in general, the automotive retail industry in particular and our customers, suppliers, vendors and business partners; our relationships with vehicle manufacturers; our ability to improve our margins; operating cash flows and availability of capital; capital expenditures; the amount of our indebtedness; the completion of any pending and future acquisitions and divestitures; future return targets; future annual savings; general economic trends, including consumer confidence levels, interest rates, and fuel prices; and automotive retail industry trends. The following are some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including: the impact of the COVID-19 pandemic, market factors, Asbury’s relationships with, and the financial and operational stability of, vehicle manufacturers and other suppliers, acts of God or other incidents which may adversely impact supply from vehicle manufacturers and/or present retail sales challenges, risks associated with Asbury’s indebtedness (including available borrowing capacity, compliance with its financial covenants and ability to refinance or repay such indebtedness, on favorable terms), Asbury’s relationships with, and the financial stability of, its lenders and lessors, risks related to competition in the automotive retail and service industries, general economic conditions both nationally and locally, governmental regulations, legislation, adverse results in litigation and other proceedings, and Asbury’s ability to execute its technology initiatives and other operational strategies, Asbury’s ability to leverage gains from its dealership portfolio, including its ability to realize the expected benefits of the acquisition of the Park Place dealership group, Asbury’s ability to capitalize on opportunities to repurchase its debt and equity securities or purchase properties that it currently leases, and Asbury’s ability to stay within its targeted range for capital expenditures. There can be no guarantees that Asbury’s plans for future operations will be successfully implemented or that they will prove to be commercially successful. These risks, uncertainties and other factors are disclosed in Asbury’s Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and other periodic and current reports filed with the Securities and Exchange Commission from time to time.  These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/asbury-automotive-group-to-unveil-clicklane-301178557.html

SOURCE Asbury Automotive Group, Inc.

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

SMITHS FALLS, ON, Nov. 23, 2020 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

The study was commissioned to evaluate the solubility, stability, acute toxicity, thermotolerance, and effects on lifespan of CBD in C. elegans as part of Canopy Growth’s ongoing commitment to provide the data required to support and influence public policy through research. To the best of the Company’s knowledge, this study represents the first long-term toxicity and lifespan research regarding the effects of chronic exposure to cannabidiol – one of the cannabinoids found in cannabis.

Acute and long-term exposure studies of CBD at physiologically relevant concentrations were studied in the worm model Caenorhabditis elegans (C. elegans) on the basis that 60-80% of their genes are shared with humans, and their comparatively short lifespan of 2-3 weeks makes such studies feasible. In the C. elegans model, which is recognized as a valid model for this kind of research, CBD did not demonstrate any degree of acute or life-long toxicity or related liabilities at physiological concentrations. Instead, CBD extended mean lifespan up to 18% and increased late-stage life activity by up to 206% compared to the untreated controls within the study.

“Despite widespread use of CBD, no life-long toxicity studies had been conducted to date to determine the impact – or potential impact – of long-term exposure to CBD,” shared Hunter Land, Senior Director of Translational and Discovery Science at Canopy Growth. “These results serve as the only CBD life-long exposure data in an in vivo model to date, and the absence of long-term toxicity gives us the evidence we need as an industry to continue researching the potential health benefits for the broader application of CBD.”

The study was conducted in partnership with NemaLife Inc., and is published in Cannabis and Cannabinoid Research journal and available online.

While further research into the life-long use of CBD should be carried out in mammalian models, the C. elegans model indicates a lack of long-term toxicity at physiologically relevant concentrations. Canopy Growth and its medical division Spectrum Therapeutics continue to advance a range of research initiatives aimed at furthering the understanding of – and unleashing – the full potential of cannabis.

About Canopy Growth Corporation

Canopy Growth (TSX:WEED,NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements

This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws (collectively, “forward-looking statements”), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward–looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward–looking statements and the forward–looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to Canopy Growth Corporation (“Canopy”) can be found under the section entitled “Risk Factors” in Canopy’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at www.sec.gov/edgar and www.sedar.com, respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward–looking statement included in this press release is made as of the date of this press release and, except as required by law, Canopy disclaims any obligation to update or revise any forward– looking statement. Readers are cautioned not to put undue reliance on any forward–looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-announces-completion-of-study-on-the-long-term-effects-of-cbd-301178311.html

SOURCE Canopy Growth Corporation

MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

• The Piper Sandler 32^nd Virtual Annual Healthcare Conference.
• The Evercore ISI 3^rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 4:20 p.m. Eastern Time.

A replay of the pre-recorded Piper Sandler fireside chat is currently available in the News & Events section of Milestone’s website at www.milestonepharma.com, and a live webcast of the Evercore fireside chat can be accessed in the same section of Milestone’s website. An archived replay of the webcasts will be available on the same website for approximately 90 days following the presentations.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma. 

Contact

David Pitts

Argot Partners
212-600-1902
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301178279.html

SOURCE Milestone Pharmaceuticals, Inc.